Core Viewpoint - The company Yifan Pharmaceutical has successfully completed the first shipment of its innovative drug F-627 to the U.S. market, marking a significant milestone in its international expansion [1] Group 1: Product Launch - F-627, also known as Ryzneuta, is the world's first third-generation long-acting G-CSF drug for increasing white blood cell counts [1] - The drug has received approval for sale in multiple regions, including China, the U.S., the EU, and Brazil [1] Group 2: Market Expectations - Based on current order conditions, the company anticipates shipping approximately 40,000 units overseas by 2025 [1] - The drug has been successfully included in China's medical insurance directory following negotiations in 2023 [1]

Core Viewpoint - The announcement details the pledge and release of shares by Cheng Xianfeng, the controlling shareholder of Yifan Pharmaceutical Co., Ltd, indicating changes in shareholding structure and potential implications for the company's stock performance [2][4]. Share Pledge Details - Cheng Xianfeng pledged 5.24% of his shares, amounting to 2.14% of the company's total share capital, starting from May 25, 2025 [2]. - The pledge was made to China Galaxy Securities Co., Ltd [2]. Share Release Details - Cheng Xianfeng released 22,000,000 shares, which represents 4.43% of his total holdings and 1.81% of the company's total share capital, effective from May 27, 2025 [2]. - The shares were also released from pledge to China Galaxy Securities Co., Ltd [2]. Cumulative Pledge Situation - As of the announcement date, Cheng Xianfeng and his concerted actors have a total of pledged shares, with the cumulative pledged amount being significant [2]. - The report indicates the proportion of pledged shares relative to total holdings and the company's total share capital [2][4].

证券代码：002019 证券简称：亿帆医药 公告编号：2025-036 亿帆医药股份有限公司 关于控股股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 三、股东股份累计被质押的情况 截至本公告披露日，程先锋先生及其一致行动人所持股份质押情况如下： | 股东名称 | 持股数 量 | 持股比 | 累计质押 数量 | 占其所 持股份 | | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 占公司总 | 已质押股份 | 占已质 | 未质押股份 | 占未质 | | | | 例 | | | 股本比例 | 限售和冻结 | 押股份 | 限售和冻结 | 押股份 | | | （股） | | （股） | 比例 | | | | | | | | | | | | | 数量（股） | 比例 | 数量（股） | 比例 | | 程先锋 | 496,526, | 40.82 | 69,500,00 | 14.00% | ...

Group 1 - The company has approved a cash dividend distribution plan for the year 2024, proposing to distribute 1 RMB per 10 shares to all shareholders, totaling approximately 121.64 million RMB [1][2] - The distribution will be based on the company's total share capital of 1,216,390,085 shares, excluding repurchased shares, with adjustments made if the total share capital changes before the distribution [1][2] - The dividend tax rates will vary for different types of shareholders, with specific provisions for Hong Kong investors and domestic investors holding different classes of shares [1][2] Group 2 - The record date for the dividend distribution is set for May 28, 2025, and the ex-dividend date is May 29, 2025 [2] - The distribution will be directly credited to the shareholders' accounts through their custodial securities companies or other custodial institutions [2] - The company assumes all legal responsibilities and consequences for any insufficient cash dividends distributed [2]

035 证券代码：002019 证券简称：亿帆医药 公告编号：2025- 4、本次实施分派方案距股东会审议通过的时间未超过两个月。 二、权益分派方案 本公司2024年年度权益分派方案为：以公司现有总股本剔除已回购股份0股 后的1,216,390,085股为基数，向全体股东每10股派1.000000元人民币现金（含税； 扣税后，通过深股通持有股份的香港市场投资者（特别说明：请上市公司根据自 身是否属于深股通标的证券，确定权益分派实施公告保留或删除该类投资者）、 境外机构（含QFII、RQFII）以及持有首发前限售股的个人和证券投资基金每10 股派0.900000元；持有首发后限售股、股权激励限售股及无限售流通股的个人股 息红利税实行差别化税率征收，本公司暂不扣缴个人所得税，待个人转让股票时， 根据其持股期限计算应纳税额【注】；持有首发后限售股、股权激励限售股及无 亿帆医药股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）2024年年度权益分派方案已获 2025年5月20日召开的2 ...

法律意见书 根据《中华人民共和国公司法》（下称《公司法》）、《中华人民共和国证 券法》（下称《证券法》）、中国证券监督管理委员会（下称"中国证监会"） 《上市公司股东会规则》（下称《股东会规则》）以及《亿帆医药股份有限公司 公司章程》（下称《公司章程》）等有关规定，安徽天禾律师事务所接受亿帆医 药股份有限公司（下称"亿帆医药"或"公司"）委托，指派王炜、罗明伟律师 （下称"天禾律师"）出席公司 2024 年年度股东会（下称"本次股东会"）， 对本次股东会相关事项进行见证，并出具法律意见。 本法律意见书是天禾律师根据对有关本次股东会事实的了解及对我国现行 法律、法规和规范性文件的理解而做出的。 天禾律师同意将本法律意见书作为本次股东会的必备文件予以公告并依法 对所出具的法律意见书承担责任。 天禾律师根据有关法律、法规的要求，按照律师行业公认的业务标准、道德 规范和勤勉尽责的精神，对本次股东会的召集和召开程序、出席会议人员的资格、 表决程序及其他相关法律问题发表法律意见如下： 一、本次股东会的召集与召开程序 （一）2025 年 4 月 24 日，公司召开第八届董事会第十六次会议，通过了《关 于召开 2024 年年 ...

亿帆医药股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 1、本次股东会无否决提案的情形。 2、本次股东会未涉及变更以往股东会已通过的决议。 证券代码：002019 证券简称：亿帆医药 公告编号：2025-034 （一）会议召开情况 一、会议召开和出席情况 1、会议召开的日期、时间 现场会议召开的时间：2025 年 5 月 20 日下午 1:30 起 网络投票的时间：2025 年 5 月 20 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 5 月 20 日上午 9:15 至 9:25，9:30 至 11:30，下午 13:00 至 15:00； 通过深圳证券交易所互联网投票系统进行网络投票，开始时间为 2025 年 5 月 20 日上午 9:15 至下午 15:00。 2、现场会议召开地点：安徽省合肥市肥西县桃花镇繁华大道与文山路交口， 合肥亿帆生物制药有限公司会议室 3、召集人：公司董事会 4、会议方式：本次会议采取现场投票和网络投票相结合的方式 5、会议主持人：董事长程先锋 ...

Core Viewpoint - The A-share market shows positive momentum with the Shanghai Composite Index closing above the annual line, indicating a slight increase of 0.23% and a total trading volume of 1,076.285 billion yuan [1]. Group 1: Market Performance - As of 13:59 today, the Shanghai Composite Index stands at 3,377.11 points, reflecting a year-to-date performance above the annual line [1]. - A total of 49 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1]. Group 2: Notable Stocks - The stocks with the largest deviation rates include: - Baoxin Technology (002514) with a deviation rate of 5.49% and a daily increase of 9.93% [1]. - ST Zhongzhu (600568) with a deviation rate of 4.76% and a daily increase of 5.22% [1]. - King Med (603882) with a deviation rate of 4.28% and a daily increase of 4.42% [1]. - Other stocks that have just crossed the annual line include: - Duofu Du (002506) with a deviation rate of 4.02% and a daily increase of 9.95% [1]. - Shapais (300791) with a deviation rate of 4.16% and a daily increase of 4.67% [1]. Group 3: Trading Data - The total trading volume for A-shares today reached 1,076.285 billion yuan, indicating active market participation [1]. - The stocks listed show varying turnover rates, with some stocks like Baoxin Technology and ST Zhongzhu having turnover rates of 9.92% and 1.36% respectively [1].

Group 1: Company Performance and Market Outlook - The company has no current plans for share reduction despite market fluctuations [2] - The domestic market for G-CSF reached nearly 10 billion RMB in 2022, indicating significant demand [9] - The company expects to ship approximately 40,000 units of overseas orders in 2025, including shipments to the U.S. market [3] Group 2: Product Development and Clinical Trials - F-652 is undergoing clinical trials with a focus on alcohol-related liver disease, with ongoing internal strategy discussions to mitigate risks [22] - The F-627 product is expected to launch in the U.S. around June 2025, with a projected shipment of 270,000 units [17] - The company anticipates that the new cell toxic production line in Hefei will be completed as scheduled [2] Group 3: Investor Relations and Communication - Investors expressed concerns about the company's communication effectiveness, particularly regarding the management's responsiveness to shareholder inquiries [5] - The company acknowledges the need for improved investor relations and plans to enhance communication strategies [21] - The management is committed to ensuring that the stock price reflects the company's true value and will work on investor engagement [21] Group 4: Financial Management and Market Strategy - The company reported a 13.55% decrease in net profit due to lower gross margins from synthetic biological products and the impact of centralized procurement [20] - The company is focusing on maintaining competitive pricing and expanding market share in the vitamin B5 sector despite current price pressures [20] - The company plans to leverage its strengths in quality and production capacity to sustain its market leadership in the vitamin sector [20]

Core Insights - The company reported a significant increase in revenue and net profit for 2024, with total revenue reaching 5.16 billion yuan, a year-on-year growth of 26.84%, and a net profit of 386 million yuan, up 170.04% [1] - The company continues to optimize its product structure and has effectively controlled expenses, with a notable improvement in expense ratios [1] Financial Performance - In 2024, the company achieved a total revenue of 5.16 billion yuan, with pharmaceutical-related revenue accounting for 4.26 billion yuan, representing over 80% of total revenue [1] - The proprietary pharmaceutical products generated 3.664 billion yuan, a year-on-year increase of 50.64%, and accounted for 71.02% of total revenue, an increase of 11.23 percentage points from the previous year [1] - For Q1 2025, the company reported revenue of 1.327 billion yuan, a slight increase of 0.05%, and a net profit of 153 million yuan, up 4.83% [1] Product Development and Innovation - The innovative drug Yilishu has received approvals from multiple regulatory bodies and has been launched in 34 countries, with over 270,000 units shipped [2] - In Q1 2025, revenue from innovative drug products increased by 327.73%, with Yilishu shipments growing by 293.64% [2] - The company is advancing several clinical trials, including F-652 for alcohol-related liver disease and a pediatric flu treatment [2] Investment Outlook - The company is expected to continue its growth trajectory, with projected revenues of 6.183 billion yuan, 7.108 billion yuan, and 7.683 billion yuan for 2025-2027, representing year-on-year growth rates of 19.83%, 14.96%, and 8.08% respectively [3] - Net profits for the same period are forecasted to be 614 million yuan, 712 million yuan, and 853 million yuan, with corresponding EPS of 0.50, 0.59, and 0.70 yuan [3] - The current stock price corresponds to PE ratios of 22.81, 19.68, and 16.43 for 2025-2027 [3]